NASDAQ:VTGN Vistagen Therapeutics (VTGN) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free VTGN Stock Alerts $4.37 -0.11 (-2.46%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.33▼$4.5350-Day Range$3.92▼$5.4052-Week Range$1.62▼$24.71Volume106,543 shsAverage Volume195,940 shsMarket Capitalization$118.08 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vistagen Therapeutics alerts: Email Address Vistagen Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside334.8% Upside$19.00 Price TargetShort InterestHealthy4.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector521st out of 925 stocksPharmaceutical Preparations Industry244th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingVistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVistagen Therapeutics has received no research coverage in the past 90 days.Read more about Vistagen Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.86% of the float of Vistagen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistagen Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Vistagen Therapeutics has recently decreased by 8.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVistagen Therapeutics does not currently pay a dividend.Dividend GrowthVistagen Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTGN. Previous Next 2.8 News and Social Media Coverage News SentimentVistagen Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vistagen Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vistagen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.96% of the stock of Vistagen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of Vistagen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vistagen Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vistagen Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.00) per share.Price to Book Value per Share RatioVistagen Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vistagen Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Vistagen Therapeutics Stock (NASDAQ:VTGN)Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Read More VTGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTGN Stock News HeadlinesMay 7, 2024 | businesswire.comVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)May 12, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.April 26, 2024 | msn.comVistagen reports positive results for mental fatigue treatmentApril 25, 2024 | businesswire.comVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueApril 24, 2024 | seekingalpha.comVistagen Therapeutics: A Pipeline With Potential In Anxiety And DepressionApril 19, 2024 | investorplace.com7 Stocks Under $15 Predicted to Boom in the Next 2 YearsApril 9, 2024 | investorplace.comMillionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027May 12, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.April 9, 2024 | businesswire.comVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceApril 1, 2024 | finance.yahoo.comVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2March 31, 2024 | investorplace.comSecret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027March 28, 2024 | msn.comPDS Biotechnology GAAP EPS of -$1.39 beats by $0.06March 26, 2024 | finance.yahoo.com30 Countries with the Lowest Depression RatesMarch 17, 2024 | seekingalpha.comWhy VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety TreatmentsMarch 16, 2024 | finance.yahoo.comVTGN Apr 2024 10.000 callMarch 15, 2024 | cnbc.comThis overlooked corner of women's health could be a $350 billion market opportunityMarch 11, 2024 | businesswire.comVistagen to Present at Stifel 2024 Virtual CNS DaysFebruary 28, 2024 | finance.yahoo.comVistagen to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 28, 2024 | businesswire.comVistagen to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comVistagen Therapeutics Stock (NASDAQ:VTGN), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comDoes VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?February 19, 2024 | investorplace.com3 Revolutionary Biotech Stocks Poised for 10X SurgeFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial OutlookFebruary 15, 2024 | finance.yahoo.comVistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 15, 2024 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call TranscriptFebruary 14, 2024 | investorplace.com3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market WaveSee More Headlines Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/12/2024Next Earnings (Estimated)6/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VTGN CUSIPN/A CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$30.00 Low Stock Price Target$12.00 Potential Upside/Downside+334.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,250,000.00 Net Margins-3,073.51% Pretax Margin-3,073.22% Return on Equity-72.10% Return on Assets-61.24% Debt Debt-to-Equity RatioN/A Current Ratio30.76 Quick Ratio30.76 Sales & Book Value Annual Sales$1.11 million Price / Sales106.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book2.65Miscellaneous Outstanding Shares27,020,000Free Float26,766,000Market Cap$118.08 million OptionableOptionable Beta0.84 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Shawn K. Singh J.D. (Age 61)CEO & Director Comp: $600kMr. Reid G. Adler Esq. (Age 69)J.D., Chief Corporate Development Officer & General Counsel Comp: $371.88kMs. Cynthia Lynn Anderson CPA (Age 55)Chief Financial Officer Mr. Joshua Prince M.B.A. (Age 54)Chief Operating Officer Mr. Mark Adrian McPartland (Age 58)Senior Vice President of Investor Relations Comp: $300kMs. Trisha FitzmauriceSenior Vice President of Human ResourcesDr. Allen Easley Cato IIIM.D., Ph.D., Senior Vice President of Development OperationsDr. Mark J. Ginski Ph.D. (Age 52)Senior VP and Head of Chemistry, Manufacturing & Controls Mr. Mark FlatherSenior Vice President of Corporate Strategy & Capital MarketsDr. Erik Berglund M.D.Ph.D., Senior VP of Global Regulatory Affairs & PharmacovigilanceMore ExecutivesKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOImmunicNASDAQ:IMUXCartesian TherapeuticsNASDAQ:RNACKaryopharm TherapeuticsNASDAQ:KPTICoya TherapeuticsNASDAQ:COYAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 41,346 shares on 5/10/2024Ownership: 6.635%Acadian Asset Management LLCBought 32,291 shares on 5/10/2024Ownership: 0.120%Blair William & Co. ILSold 19,580 shares on 5/9/2024Ownership: 0.253%BVF Inc. ILBought 2,000,000 shares on 2/15/2024Ownership: 7.402%Great Point Partners LLCBought 1,858,735 shares on 2/15/2024Ownership: 6.879%View All Insider TransactionsView All Institutional Transactions VTGN Stock Analysis - Frequently Asked Questions Should I buy or sell Vistagen Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VTGN shares. View VTGN analyst ratings or view top-rated stocks. What is Vistagen Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued twelve-month price targets for Vistagen Therapeutics' shares. Their VTGN share price targets range from $12.00 to $30.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price. View analysts price targets for VTGN or view top-rated stocks among Wall Street analysts. How have VTGN shares performed in 2024? Vistagen Therapeutics' stock was trading at $5.14 on January 1st, 2024. Since then, VTGN shares have decreased by 15.0% and is now trading at $4.37. View the best growth stocks for 2024 here. When is Vistagen Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our VTGN earnings forecast. How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics, Inc. (NASDAQ:VTGN) issued its earnings results on Tuesday, February, 13th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.09. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.73 million. Vistagen Therapeutics had a negative net margin of 3,073.51% and a negative trailing twelve-month return on equity of 72.10%. What ETFs hold Vistagen Therapeutics' stock? ETFs with the largest weight of Vistagen Therapeutics (NASDAQ:VTGN) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares Neuroscience and Healthcare ETF (IBRN). When did Vistagen Therapeutics' stock split? Vistagen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Vistagen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP). Who are Vistagen Therapeutics' major shareholders? Vistagen Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.64%), Blair William & Co. IL (0.25%) and Acadian Asset Management LLC (0.12%). Insiders that own company stock include Commodore Capital Lp, H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par. View institutional ownership trends. How do I buy shares of Vistagen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTGN) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
